These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 8121549)
1. Primary brain tumors differ in their expression of octamer deoxyribonucleic acid-binding transcription factors from long-term cultured glioma cell lines. Schreiber E; Merchant RE; Wiestler OD; Fontana A Neurosurgery; 1994 Jan; 34(1):129-35. PubMed ID: 8121549 [TBL] [Abstract][Full Text] [Related]
2. The B cell coactivator Bob1 shows DNA sequence-dependent complex formation with Oct-1/Oct-2 factors, leading to differential promoter activation. Gstaiger M; Georgiev O; van Leeuwen H; van der Vliet P; Schaffner W EMBO J; 1996 Jun; 15(11):2781-90. PubMed ID: 8654375 [TBL] [Abstract][Full Text] [Related]
3. Expression of non-glial intermediate filament proteins in gliomas. Hirato J; Nakazato Y; Ogawa A Clin Neuropathol; 1994; 13(1):1-11. PubMed ID: 7518371 [TBL] [Abstract][Full Text] [Related]
4. Human small cell lung cancer expresses the octamer DNA-binding and nervous system-specific transcription factor N-Oct 3 (brain-2). Schreiber E; Himmelmann A; Malipiero U; Tobler A; Stahel R; Fontana A Cancer Res; 1992 Nov; 52(21):6121-4. PubMed ID: 1327524 [TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions. Wang D; Yamamoto S; Hijiya N; Benveniste EN; Gladson CL Oncogene; 2000 Nov; 19(50):5801-9. PubMed ID: 11126367 [TBL] [Abstract][Full Text] [Related]
6. Differentiation of human B-cell malignant lymphomas is independent of the octamer lymphoid specific binding factor (Oct-2). Kossakowska AE; Urbanski SJ Immunology; 1991 Sep; 74(1):37-43. PubMed ID: 1937571 [TBL] [Abstract][Full Text] [Related]
7. N-Oct 5 is generated by in vitro proteolysis of the neural POU-domain protein N-Oct 3. Atanasoski S; Schreiber E; Fontana A; Herr W Oncogene; 1997 Mar; 14(11):1287-94. PubMed ID: 9178889 [TBL] [Abstract][Full Text] [Related]
8. Characteristic patterns of N Oct-3 binding to a set of neuronal promoters. Blaud M; Vossen C; Joseph G; Alazard R; Erard M; Nieto L J Mol Biol; 2004 Jun; 339(5):1049-58. PubMed ID: 15178247 [TBL] [Abstract][Full Text] [Related]
9. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Somasundaram K; Reddy SP; Vinnakota K; Britto R; Subbarayan M; Nambiar S; Hebbar A; Samuel C; Shetty M; Sreepathi HK; Santosh V; Hegde AS; Hegde S; Kondaiah P; Rao MR Oncogene; 2005 Oct; 24(47):7073-83. PubMed ID: 16103883 [TBL] [Abstract][Full Text] [Related]
10. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs. Nabors LB; Gillespie GY; Harkins L; King PH Cancer Res; 2001 Mar; 61(5):2154-61. PubMed ID: 11280780 [TBL] [Abstract][Full Text] [Related]
11. Identification of MG-160, a FGF binding medial Golgi sialoglycoprotein, in brain tumors: an index of malignancy in astrocytomas. Yamaguchi F; Morrison RS; Gonatas NK; Takahashi H; Sugisaki Y; Teramoto A Int J Oncol; 2003 May; 22(5):1045-9. PubMed ID: 12684670 [TBL] [Abstract][Full Text] [Related]
12. Mdr1 mRNA expression differs between grade III astrocytomas and glioblastomas. Kirches E; Oda Y; Von Bossanyi P; Diete S; Schneider T; Warich-Kirches M; Dietzmann K Clin Neuropathol; 1997; 16(1):34-6. PubMed ID: 9020393 [TBL] [Abstract][Full Text] [Related]
13. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179 [TBL] [Abstract][Full Text] [Related]
14. Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B--induced gliomagenesis. Ferletta M; Uhrbom L; Olofsson T; Pontén F; Westermark B Mol Cancer Res; 2007 Sep; 5(9):891-7. PubMed ID: 17855658 [TBL] [Abstract][Full Text] [Related]
15. The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Thomson JA; Murphy K; Baker E; Sutherland GR; Parsons PG; Sturm RA; Thomson F Oncogene; 1995 Aug; 11(4):691-700. PubMed ID: 7651733 [TBL] [Abstract][Full Text] [Related]
16. Telomerase activity and alterations in telomere length in human brain tumors. Hiraga S; Ohnishi T; Izumoto S; Miyahara E; Kanemura Y; Matsumura H; Arita N Cancer Res; 1998 May; 58(10):2117-25. PubMed ID: 9605755 [TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of a novel BR-2 gene that is down-regulated in human low grade glioma tumors. Wei KC; Berger MS; Sehgal A Anticancer Res; 2002; 22(2A):649-57. PubMed ID: 12014633 [TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of a novel human brain tumor-associated gene BR-3. Weil KC; Berge MS; Sehgal A Anticancer Res; 2002; 22(3):1467-74. PubMed ID: 12168825 [TBL] [Abstract][Full Text] [Related]
19. Reduced TSC2 RNA and protein in sporadic astrocytomas and ependymomas. Wienecke R; Guha A; Maize JC; Heideman RL; DeClue JE; Gutmann DH Ann Neurol; 1997 Aug; 42(2):230-5. PubMed ID: 9266734 [TBL] [Abstract][Full Text] [Related]
20. Glutamate-induced octamer DNA binding and transcriptional control in cultured radial glia cells. López-Bayghen E; Cruz-Solís I; Corona M; López-Colomé AM; Ortega A J Neurochem; 2006 Aug; 98(3):851-9. PubMed ID: 16787415 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]